These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2442312)

  • 1. Intracavitary administration of biological agents.
    Markman M
    J Biol Response Mod; 1987 Aug; 6(4):404-11. PubMed ID: 2442312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with lymphokine combinations.
    Mulé JJ; Rosenberg SA
    Important Adv Oncol; 1989; ():99-126. PubMed ID: 2468602
    [No Abstract]   [Full Text] [Related]  

  • 3. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal chemotherapy for ovarian carcinoma.
    Markman M
    Biomed Pharmacother; 1987; 41(8):420-4. PubMed ID: 3330457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
    Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
    Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of intraperitoneal chemotherapy in the front-line setting.
    Markman M
    J Clin Oncol; 2003 May; 21(10 Suppl):145s-148s. PubMed ID: 12743130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 1998; 70(5):32-7. PubMed ID: 9644739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines and monoclonal antibodies. Immunologic approaches to tumor therapy].
    Pfreundschuh M
    Fortschr Med; 1986 Dec; 104(47-48):973-6. PubMed ID: 2434398
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intravesical therapy: Influence on superficial bladder cancer progression].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BCG therapy. Its role in the treatment of tumors of the bladder].
    Patard JJ; Chopin DK; Abbou CC
    Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokines as clinical adjuvants: how far are we?
    Villinger F
    Expert Rev Vaccines; 2003 Apr; 2(2):317-26. PubMed ID: 12899581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local reaction to subconjunctival injections of MER/BCG.
    Navon D; Zonis S; Meyer E; Alon U; Bartal A; Gilhar A
    Metab Pediatr Ophthalmol; 1981; 5(3-4):243-5. PubMed ID: 7311664
    [No Abstract]   [Full Text] [Related]  

  • 15. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2.
    Dillman JB
    J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
    Han RF; Pan JG
    Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy in ovarian cancer.
    Hofstra LS; de Vries EG; Mulder NH; Willemse PH
    Cancer Treat Rev; 2000 Apr; 26(2):133-43. PubMed ID: 10772970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.